by David Wallace Hepcidin Mimetic PTG-300 Promising Treatment for PV How does PTG-300 work to reduce or eliminate the need for phlebotomy in PV? How does iron deficiency play a role in polycythemia vera? What are the goals of this treatment? Leading MPN expert, Dr. Srdan Verstovsek, from MD Anderson Cancer Center, interviews with David […]
Protagonist Therapeutics early Phase 2 results for Polycythemia Vera Treatment Encouraging
5:01 pm By
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
Constellation Pharmaceuticals Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis
3:00 pm By
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) – Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update on progress in the MANIFEST Phase 2 clinical trial of CPI-0610 in myelofibrosis (MF). The Company also reviewed its 2018 accomplishments and announced its data […]
Incyte conducts Phase 2 Clinical Trials for Myelofibrosis and Essential Thrombocythemia
4:48 pm By
Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are interested in participating […]
A thrombopoietin receptor antagonist is capable of depleting MF hematopoietic stem and progenitor cells
10:06 pm By
The following abstract involved the work of Dr Ron Hoffman, the principle investigator (PI), senior member of the MPN group at Mt Sinai Hospital in New York City as well as the PI of the MPN-RC. Xiaoli Wang, Phd, performed all of the lab work. Dr John Mascarenhas was my point of contact for this […]
Concomitant JAK2 V617F-positive PV and BCR-ABL-positive CML with ruxolitinib and dasatinib
7:22 pm By
Citation: Blood Cancer Journal (2015) 5, e351; doi:10.1038/bcj.2015.77 Published online 2 October 2015 The combination of ruxolitinib and dasatinib was safe and effective in the treatment of concomitant PV and CML in this patient A Zhou1, E M Knoche1, E K Engle1, D A C Fisher1 and S T Oh1 1Division of Hematology, Washington University School of Medicine, St Louis, MO, USA […]
MPN Clinical Trial Highlights for Summer 2015
8:20 am By
by mpdsupport.org Clinical Trials for MPNs are on the Rise! If you have MF, PV or ET but don’t need medication now, you may think that clinical trials don’t matter to you. But that could change, at which point you may want to review your options. Thankfully, over the past years the interest in developing […]
New blood cancer drug reaches cells hiding in bone marrow
2:11 am By
A new drug aimed at dormant cancer stem cells that hide in the hypoxic zones of bone marrow that most other drugs can’t reach is currently in 5 clinical trials. Source: New blood cancer drug reaches cells hiding in bone marrow – UPI.com
MPN Clinical Trial updates from Geron and Promedior
9:47 pm By
Geron announces removal of Full Clinical Hold on Imetelstat The full clinical hold on Geron’s sole pipeline candidate, investigation new drug (IND), Imetelstat, has been lifted by the FDA. The company does not intend to conduct further studies or develop imetelstat for the treatment of essential thrombocythemia (ET) or polycythemia vera (PV). The development plan […]
High levels of Inflammation disrupt normal blood formation potentially leading to leukemia
3:23 pm By
Indiana University researchers identify events causing bone marrow inflammation leading to blood disorders Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia. “It has been known for years that there are […]
Imetelstat Trials for MF moves forward as FDA removes hold
3:14 pm By
Geron Corp announced today that the partial clinical hold on clinical trials of imetelstat in myelofibrosis has been removed by the FDA. The hold for essential thrombocythemia and polycythemia vera remains. Click here for the full story.
Jakafi One Step Closer to Approval for Polycythemia Vera
1:50 pm By
Jakafi Improves Symptoms in PV In phase 3 randomized controlled trial, Jakafi (ruxolitinib) improved several key symptoms in polycythemia vera, according to Dr Srdan Verstovsek of MD Anderson Cancer Center in Houston. Results from the RESPONSE trial were presented at the 2014 ASCO (American Society of Clinical Oncology) annual meeting in Chicago. PV is a […]
Impact of JAK-inhibitor therapy on inflammation-mediated comorbidities in MPNs
11:07 am By
by Dr. Hans C Hasselbalch Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, […]
Geron’s Clinical Trials of Imetelstat put on Hold
12:23 pm By
FDA asks Geron to Halt Development of Imetelstat The FDA has placed it’s only pipeline candidate, imetelstat, on full clinical hold. The news sent shares of GERN plunging 61% on March 12, 2014. Geron had submitted an Investigation New Drug (IND) application for imetelstat, but the FDA issued a verbal notice halting the trials. This […]
MPD-RC 111 Clinical Trial for High Risk Polycythemia Vera or Essential Thrombocythemia
5:12 am By
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the Myeloproliferative Disorders Research Consortium (MPD-RC 111), a clinical trial investigating single arm salvage therapy with pegylated interferon alfa-2a for patients with high risk polycythemia vera or high risk essential […]
MPD-RC 112 Clinical Trial for High Risk PV and ET Patients
3:36 pm By
Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Key Points: Why are we doing the Study? Top […]
Reversal Of Bone Marrow Fibrosis in Myelofibrosis
6:17 pm By
Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis Geron is studying Imetelstat as a treatment for Myelofibrosis, a disease in which abnormal blood cells build up in the bone marrow, forming thick scar tissues that slows the production of healthy blood cells. Other MF drugs treat the symptoms of the disease (Jakafi). […]
MPN Clinical Trials Moving Forward
9:27 pm By
Two MPN Clinical Trials Progress – Phase 3 Polycythemia Vera Study and Phase 2 Myelofibrosis Study There are dozens of clinical trials at various stages of progression for Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. Some are in the recruiting stage, others still active and the balance have been completed. Both of these trials will be […]
Follow Us!